Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas

被引:0
作者
Nagy, Monika [1 ]
Schulz-Ertner, Daniela [1 ]
Bischof, Marc [1 ]
Welzel, Thomas [1 ]
Hof, Holger [1 ]
Debus, Juergen [1 ]
Combs, Stephanie E. [1 ]
机构
[1] Univ Heidelberg Hosp, Dept Radiat Oncol, Heidelberg, Germany
来源
TUMORI JOURNAL | 2009年 / 95卷 / 03期
关键词
astrocytoma; glioma; radiotherapy; outcome; ACCELERATED HYPERFRACTIONATED RADIOTHERAPY; SUPRATENTORIAL MALIGNANT GLIOMAS; MULTIVARIATE DATA-ANALYSIS; PHASE-II; RADIATION-THERAPY; VINCRISTINE CHEMOTHERAPY; GLIOBLASTOMA-MULTIFORME; FINAL REPORT; SURVIVAL; TRIAL;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. Patients with anaplastic gliomas have a more favorable overall Survival than patients with glioblastomas. in most analyses, WHO grade III and IV tumors are not analyzed separately. The present analysis reports Outcome after postoperative radiotherapy in patients with WHO grade III gliomas. Patients and methods. Between January 1988 and January 2007, 127 patients with WHO grade III tumors were treated with radiotherapy; the histological classification was pure astrocytoma in 104 patients, oligoastrocytoma in 12 and pure oligodendroglioma in 11 patients. Median age was 48 years. After the primary diagnosis, a biopsy had been performed in 72 patients; Subtotal and total resections were performed in 37 and 18 patients, respectively. In all patients radiotherapy was applied with a median dose of 60 Gy in conventional fractionation. The median follow-Lip time was 18 months. Results. Median overall Survival was 17 months. Overall survival was significantly influenced by the extent of surgery. Median overall survival was 32 months after complete resection, 36 months after subtotal resection, and 12 months after biopsy. Median overall survival was 7 months for patients with anaplastic astrocytomas, 44 months for patients with mixed tumors, and 47 months for those with pure oligodendrogliomas. Age significantly influenced overall Survival. Median progression-free survival was 9 months; the extent of neurosurgical resection significantly influenced progression-free survival. Conclusion. Patients with WHO grade III anaplastic astrocytomas, oligodendrogliomas and oligoastrocytomas show favorable overall Survival after postoperative radiotherapy compared with glioblastoma patients and should therefore be analyzed separately. Radiochemotherapy might further improve Outcome.
引用
收藏
页码:317 / 324
页数:8
相关论文
共 67 条
  • [1] Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas
    Bauman, GS
    Ino, Y
    Ueki, K
    Zlatescu, MC
    Fisher, BJ
    Macdonald, DR
    Stitt, L
    Louis, DN
    Cairncross, JG
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (03): : 825 - 830
  • [2] Modifying radical radiotherapy in high grade gliomas; Shortening the treatment time through acceleration
    Brada, M
    Sharpe, G
    Rajan, B
    Britton, J
    Wilkins, PR
    Guerrero, D
    Mines, F
    Traish, D
    Ashley, S
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 43 (02): : 287 - 292
  • [3] Survival Analysis Part II: Multivariate data analysis - an introduction to concepts and methods
    Bradburn, MJ
    Clark, TG
    Love, SB
    Altman, DG
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 (03) : 431 - 436
  • [4] Survival Analysis Part III: Multivariate data analysis - choosing a model and assessing its adequacy and fit
    Bradburn, MJ
    Clark, TG
    Love, SB
    Altman, DG
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 (04) : 605 - 611
  • [5] Buckner JC, 2001, CANCER-AM CANCER SOC, V92, P420, DOI 10.1002/1097-0142(20010715)92:2<420::AID-CNCR1338>3.0.CO
  • [6] 2-3
  • [7] BURGER PC, 1985, CANCER-AM CANCER SOC, V56, P1106, DOI 10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO
  • [8] 2-2
  • [9] Cairncross G, 2004, J CLIN ONCOL, V22, p107S
  • [10] CHEMOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIOMA
    CAIRNCROSS, G
    MACDONALD, D
    LUDWIN, S
    LEE, D
    CASCINO, T
    BUCKNER, J
    FULTON, D
    DROPCHO, E
    STEWART, D
    SCHOLD, C
    WAINMAN, N
    EISENHAUER, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (10) : 2013 - 2021